"LEQEMBI®" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

"LEQEMBI®" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corp…

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

TOKYO and CAMBRIDGE, Mass., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that humanized anti-soluble aggregated amyloid-beta…

17M Patient Market: China Approves LEQEMBI's Extended Dosing for Early Alzheimer's Treatment

LEQEMBI approved for 4-week maintenance dosing in China for early Alzheimer's disease. Targets 17M patients with MCI/mild dementia. Unique dual action against amyloid plaques and protofibrils.